Slide 1: CTS Corporation 2nd Quarter 2026 Earnings Call
CTS Corporation 2nd Quarter 2026 Earnings Call July 28, 2026
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, “forward-
Slide 3: Q2 2026 – Strong Diversification Momentum Drives Record Margins and Profitability
Q2 2026 – Strong Diversification Momentum Drives Record Margins and Profitability • Solid execution in Q2 - Revenue increased 7% YoY and 4% Vs Q1 2026 - Book-to-bill ratio2 of 1.1 Second Quarter - Adj. gross margin expanded 270 bps • Continued momentum in diversified end markets $145M 41.5% $0.74 Re
Slide 4: End Markets Update: Medical and Aerospace & Defense
End Markets Update Revenue • Q2 sales up 45% Vs Q2 2025; 14% Vs Q1 2026 ($ Millions) • Book-to-bill 1.21, bookings up 14% vs Q2 2025 Medical $28 $25 • Strong partnership with customers for next- $19 generation product development • Sustained strong demand for diagnostics and Q2 2025 Q1 2026 Q2 2026
Slide 5: End Markets Update: Industrial and Transportation
End Markets Update Revenue ($ Millions) • Q2 sales up 16% Vs Q2 2025; 6% Vs Q1 2026 Industrial $40 • Strong bookings - Book-to-bill ratio 1.11 $37 $34 • Solid momentum across diverse set of applications Q2 2025 Q1 2026 Q2 2026 • Added 2 new customers Revenue • Q2 sales down 2% year over year Transpo
Slide 6: FY 2026 Updated Guidance
FY 2026 Updated Guidance Revenue Adjusted Diluted EPS 1 ($ Millions) $585 $2.70 $2.55 $565 $550 $541 $515 $2.22 $2.23 $2.12 2023 2024 2025 2026F 2023 2024 2025 2026F Key Outlook Assumptions - Continuation of current market conditions – Ongoing monitoring of near-term economic impacts, including geop
Slide 7: Financials
Financials 7
Slide 8: Q2 2026 Financial Summary
Q2 2026 Financial Summary Results Highlights ($ Millions, except percentages and per share amounts) • Revenue up 7% year over year and 4% sequentially; Revenue $145 $1.4m currency benefit in the quarter $139 $135 • Diversified end market revenue up 15% vs Q2 2025 • Transportation revenue down 2% yea
Slide 9: Prioritizing Strong Cash Flow Generation
Prioritizing strong cash flow generation Q2 YTD Operating Cash Flow Cash and Debt1 ($ Millions) ($ Millions) $51 $300 Total Facility $44 $38 $108 $55 Borrowed 2024 2025 2026 Cash Debt $41M $15M 2 3 YTD Q2 2026 Free Cash Flow Cash Returned to Shareholders YTD Q2 2026 $10M Strong Balance Sheet YTD Q2
Slide 10: Q&A
Q&A cts
Slide 11: Appendix
Appendix cts
Slide 12: Non-GAAP Financial Measures
Non-GAAP Financial Measures From time to time, CTS may use non-GAAP financial measures in discussing CTS’ business. These measures are intended to supplement, not replace, CTS’ presentation of its financial results in accordance with U.S. GAAP. CTS believes that the non-GAAP financial measures prese
Slide 13: Regulation G Schedules: Adjusted Gross Margin
Regulation G Schedules Adjusted Gross Margin ($ Millions, except percentages) Three Months Ended Six Months Ended Three Months Twelve Months Ended June 30, June 30, Ended March 31, December 31, 2026 2025 2026 2025 2026 2025 2024 2023 Gross margin $ 60.0 $ 52.4 $ 115.0 $ 99.0 $ 55.0 $ 208.0 $ 187.6 $
Slide 14: Regulation G Schedules: Adjusted Operating Earnings
Regulation G Schedules Adjusted Operating Earnings ($ Millions, except percentages) Three Months Ended Six Months Ended Twelve Months Ended June 30, June 30, December 31, 2026 2025 2026 2025 2025 2024 2023 Operating earnings $ 26.8 $ 22.7 $ 48.8 $ 39.0 $ 82.6 $ 71.2 $ 75.1 Net sales $ 144.8 $ 135.3
Slide 15: Regulation G Schedules: Adjusted EBITDA Margin
Regulation G Schedules Adjusted EBITDA Margin ($ Millions, except percentages) Three Months Ended Six Months Ended Three Months Twelve Months Ended June 30, June 30, Ended March 31, December 31, 2026 2025 2026 2025 2026 2025 2024 2023 Net earnings $ 19.2 $ 18.5 $ 36.4 $ 31.9 $ 17.2 $ 65.3 $ 55.5 $ 6
Slide 16: Regulation G Schedules: Adjusted Net Earnings and Adjusted Diluted EPS
Regulation G Schedules Adjusted Net Earnings and Adjusted Diluted Earnings Per Share ($ Millions, except percentages and per share amounts) Three Months Ended Six Months Ended Three Months Ended June 30, June 30, March 31, 2026 2026 2025 2025 2026 2026 2025 2025 2026 2026 Per Share Per Share Per sha
Slide 17: Regulation G Schedules: Adjusted Net Earnings and Adjusted Diluted EPS
Regulation G Schedules Adjusted Net Earnings and Adjusted Diluted Earnings Per Share ($ Millions, except percentages and per share amounts) Twelve Months Ended December 31, 2025 2025 2024 2024 2023 2023 Per share Per share Per share Net earnings (loss) (A) $ 65.3 $ 2.19 $ 55.5 $ 1.80 $ 60.5 $ 1.92 A
Slide 18: Regulation G Schedules
Regulation G Schedules a) Reflected in Selling, general and administrative and other income (expense), net. b) Reflected in Cost of goods sold. c) Reflected in Restructuring charges. d) Reflected in Other income (expense), net. e) Reflected in Income tax expense. For 2023, discrete tax items include
Slide 19: Free Cash Flow
Regulation G Schedules Free Cash Flow Six Months Ended ($ Millions, except percentages) Three Months Ended Twelve Months Ended June 30, June 30, December 31, 2026 2025 2026 2025 2025 2024 2023 Net cash provided by operating activities $ 33.4 $ 28.4 $ 50.7 $ 43.9 $ 102.1 $ 98.2 $ 88.8 Capital expendi